Wound Oxygen Therapy Articles & Analysis
17 news found
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
The most commonly used fractional laser is CO2 fractional laser beauty machine. After more than ten years of clinical application, it can be said that CO2 fractional laser skin resurfacing treatment technology is relatively safe. As long as its therapeutic energy and action density are mastered, there are generally no obvious side effects of. Bvlaser is a professional CO2 fractional laser ...
Aatru Medical, LLC ("Aatru") today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound ...
Medovate is delighted to be joining the Association of British HealthTech Industries (ABHI) US Accelerator 2022 cohort. The dynamic Cambridge-based development company, who are helping to bring to life pioneering medical devices, is participating in the programme for a second year running. Now in its fifth year, the ABHI US Accelerator, conducted in partnership with the Dell Medical School in ...
ByMedovate
Advanced Oxygen Therapy Inc. (AOTI), the leader in noninvasive sustained wound healing solutions, announced today a number of significant additions to its Leadership Team, bringing to the company over 100 years of combined strategic experience: Chief Medical Officer – Dr. ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
Aatru Medical, LLC ("Aatru") today announced the successful completion of the first 14 patients in their multi-center New Zealand-based clinical study of the FDA-approved NPSIMS™ Negative Pressure Surgical Incision Management System. The full Study enrollment will include plastic surgery, spinal surgery and cardiothoracic surgery closed incisions. The NPSIMS™, which contains no ...
This new 5x7 OxySpur oxygen diffusion dressing is part of the OxyGeni System which provides a complete oxygen therapy and wound monitoring system. Continuous Diffusion of Oxygen (CDO) therapy provides full closure and pain relief to patients dealing with chronic, ischemic or surgical ...
Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United States and United Kingdom. ...
Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home. ...
The article (https://thehealthcareinsights.com/advanced-oxygen-therapy-inc-dedicated-to-resolving-acute-and-chronic-wounds-through-its-unique-multi-modality-TWO2therapy/) details how AOTI is dedicated to resolving acute and chronic wounds through its patented cyclical-pressure Topical Wound ...
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved dressings and devices. The company ...
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering ...
Aatru Medical, LLC ("Aatru") announced today that its technical Abstract has been accepted for presentation at both the SAWC/WHS 2020 conference in North Carolina and also at EWMA 2020, to be held in London, England. The 2020 Symposium on Advanced Wound Care (SAWC)/Wound Healing Society (WHS) meeting is the largest gathering of wound care ...
Aatru Medical, LLC ("Aatru") is pleased to announce its recent submission to the FDA of a traditional 510(k) premarket notification application for the company's first product, NPSIMS - Negative Pressure Surgical Incision Management System. The submission efforts were led by Aatru President and Board Member Edward Armstrong, in conjunction with Coastal Consulting Group, NAMSA, and DuVal & ...
AOTI Inc. announced today that since the outbreak of the COVID-19 pandemic it has been focusing all its resources on supporting a growing number of wound care patients being treated at home by its unique multi-modality Topical Wound Oxygen (TWO2) therapy. TWO2 therapy offers a solution that is unique to the ...